OrbiMed Closes $550 Million Fund
This article was originally published in Start Up
Executive Summary
OrbiMed Advisers just closed a $550 million fund, a tick more than its previous general fund and raised mostly from previous backers. OrbiMed’s general partners say they’ll make no radical departures from their previous formula despite the upheaval brought on by the recession and the federal health care reform saga.
You may also be interested in...
Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
The dedicated health care fund says it will stick with its formula: half the fund into biopharma, the other half spread among devices, diagnostics, services, and information technology.
Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
The dedicated health care fund says it will stick with its formula: half the fund into biopharma, the other half spread among devices, diagnostics, services, and information technology.
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Despite a few bright spots, the fundraising environment remains difficult for many venture investors. Biotechs that went public during the 2005-2007 window have largely underperformed, despite hitting the stock exchanges with what plenty of CEOs and VCs felt were artificially low prices negotiated by an oligarchy of biotech IPO buyers. Moreover, pharmaceutical companies have been buying fewer, not more, biotechs - even as more companies are seemingly created with acquisition, not IPO, in mind. Meanwhile, the M&A deals that do occur are increasingly risk-sharing affairs that resemble alliances, replete with earn-out payments triggered by development, regulatory, or commercial milestones. In short: good venture exits have been extremely hard to come by. And data from Elsevier's Strategic Transactions analyzed by START-UP suggest that although these risk-sharing deal structures may be a by-product of a miserable economy, they are likely to stick around regardless of any economic turnaround.